BUPRENORPHINE

HHHRC offers buprenorphine (Suboxone®) induction at our Honolulu clinic. For questions, or to make an appointment, call the HHHRC clinic line at (808) 683-5484.

For Medical Providers 
For providers who wish to refer, please complete the Opioid Use Disorder referral form and/or call the clinic line.

For Patients
Click the button below to download our buprenorphine instruction sheet with helpful information for starting Suboxone®.

TELEHEALTH

TELEMEDICINE: VIRTUAL CLINICAL CARE FROM HHHRC IN RESPONSE TO COVID-19 OUTBREAK

We are providing a safe and convenient way for patients to continue receiving care from our three providers during this challenging time.

WHAT IS BUPRENORPHINE? From the Substance Abuse and Mental Health Services Administration (SAMHSA)

Buprenorphine is used to treat Opioid Use Disorder (OUD). Approved for clinical use in October 2002 by the Food and Drug Administration (FDA), medications such as buprenorphine, in combination with counseling and behavioral therapies, provide a whole-patient approach to the treatment of opioid dependency. When taken as prescribed, buprenorphine is safe and effective.

As with all medications used in MAT, buprenorphine is prescribed as part of a comprehensive treatment plan that includes counseling and participation in social support programs. Buprenorphine offers several benefits to those with opioid dependency and to others for whom treatment in a methadone clinic is not preferred or is less convenient.

Buprenorphine has unique pharmacological properties that help:

  • Lower the potential for misuse

  • Diminish the effects of physical dependency to opioids, such as withdrawal symptoms and cravings

  • Increase safety in cases of overdose

 

Buprenorphine is an opioid partial agonist. This means that, like opioids, it produces effects such as euphoria or respiratory depression at low to moderate doses. With buprenorphine, however, these effects are weaker than full opioid agonists such as heroin and methadone. Buprenorphine’s opioid effects increase with each dose until at moderate doses they level off, even with further dose increases. This “ceiling effect” lowers the risk of misuse, dependency, and side effects. Also, because of buprenorphine’s long-acting agent, many patients may not have to take it every day.

RESOURCES

Information about Buprenorphine from the Substance Abuse and Mental Health Services Administration (SAMHSA)

Medication to Treat Addiction Involving Opioid Use 2018 Fact Sheet from the American Society of Addiction Medicine (ASAM)

The National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use from ASAM

Hawai‘i Health & Harm Reduction Center is committed to the health and safety of our clients, community, and staff. We are monitoring the COVID-19 situation and will announce updates as we review advisories from the Hawai‘i DOH and the CDC.

.

The following changes are effective immediately and will be in place until further notice:

  • We have reduced our hours of operation. Please click here for our new temporary hours.

  • HHHRC is suspending all walk-in services except for current clients. We are not accepting new patients
    or referrals at this time, with the exception of newly diagnosed HIV+ individuals.

  • We will continue to see existing appointments as scheduled. 

.

To learn more, visit our COVID-19 page.

  • White Facebook Icon
  • social-instagram-white
  • White Twitter Icon
  • White YouTube Icon
  • email-stretch-white

Temporary Hours of Operation: 
Mon/Wed/Thurs 9:00AM - 2:00PM; Tues 1:00PM - 3:00PM; Fri 1:00PM - 5:00PM

NOTICE: HHHRC COVID-19 SERVICE INTERRUPTIONS

Address: 677 Ala Moana Blvd. Suite 226  Honolulu, HI  96813

Email: info@hhhrc.org     Tel:  (808) 521-2437

Copyright 2019 Hawai'i Health & Harm Reduction Center